Prolactin and TSH responses to TRH and to haloperidol in schizophrenic patients before and after treatment.
The prolactin (PRL) and the TSH responses to thyrotropin releasing hormone (TRH, 0.4 mg i.v.) and to haloperidol (5 mg i.m.) were studied in 11 male schizophrenic patients in a drug-free state and after treatment with haloperidol, 60 mg daily. The PRL responses observed after i.m. haloperidol in the drug-free state, on average 35.4 ng/ml, were abolished after treatment, indicating complete receptor blockade, while the PRL responses to TRH were preserved, although moderately reduced (from 19.4 to 14.8 ng/ml on average). The TSH responses to TRH were unaltered by the treatment (means 8.25 and 7.74 mIU/l). The results show that the TSH and partially the PRL releasing actions of TRH are not mediated via receptors that are effectively blocked by haloperidol.
Markianos
M
M
Athens University Medical School, Psychiatric Clinic, Eginition Hospital, Greece.
Hatzimanolis
J
J
Stefanis
C
C
D000328:Adult; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011388:Prolactin / Q000097:blood*; D011569:Psychiatric Status Rating Scales; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology*
D011954:Receptors, Dopamine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013972:Thyrotropin; D006220:Haloperidol